FDA is drawing a clear line between clinical studies intended to support biosimilarity versus those aimed at demonstrating interchangeability when it comes to the source of the comparator reference product.
Sponsors pursuing interchangeability determinations should use a US-licensed reference product in switching studies examining the effects of multiple transitions between...